Homocystinuria

Definition And Etiology

Autosomal recessive disorders of sulfur amino acid metabolism characterized by the accumulation of homocysteine in blood and urine.
Classic Homocystinuria results from a deficiency of Cystathionine $β$ -Synthase (CBS), requiring Vitamin B6 as a cofactor.
Other forms result from defects in homocysteine remethylation, such as Methylene Tetrahydrofolate Reductase (MTHFR) deficiency or Cobalamin (Vitamin B12) processing defects.

%%{init: {"theme": "base", "themeVariables": { "lineWidth": "3px", "lineColor": "#000000", "primaryColor": "#e1f5fe", "primaryBorderColor": "#01579b", "primaryTextColor": "#01579b" }}}%%
graph TD
    DA[Dietary Amino Acids] --> MET[Methionine]
    MET --> HC[Homocysteine]
    
    %% The Blocked Pathway
    HC -- "Cystathionine β-synthase (CBS) 
 (Pyridoxine-dependent)" --- BLOCK{X}
    BLOCK --> CYSTATH[Cystathionine]
    CYSTATH --> CYS[Cysteine]

    %% Remethylation Pathways (Back to Methionine)
    HC -- "Folate 
/ B12 
dependent" --> MET
    HC -- "Betaine (Alternative Pathway)" --> MET

    %% Styling specific nodes
    style BLOCK fill:#ffebee,stroke:#c62828,stroke-width:4px,color:#c62828
    style DA fill:#f1f8e9,stroke:#33691e,color:#33691e
    style CYS fill:#f1f8e9,stroke:#33691e,color:#33691e

Pathophysiology

Biochemical Defect

Defect Type	Enzyme/Cofactor	Biochemical Consequences
Classic	Cystathionine $β$ -Synthase (CBS), Vitamin B6	Failure to convert homocysteine to cystathionine. Leads to elevated homocysteine, elevated methionine, and low cysteine (cysteine becomes an essential amino acid).
Remethylation	MTHFR, Methionine Synthase, Vitamin B12	Failure to convert homocysteine back to methionine. Leads to elevated homocysteine and low methionine.

Mechanism Of Toxicity

Elevated homocysteine causes severe endothelial injury, leading to a high risk of thrombosis.
Elevated metabolites interfere with collagen and elastin cross-linking via fibrillin-1 inhibition.
Homocysteine acts as an NMDA receptor agonist, leading to neurotoxicity and seizures.

Clinical Features

Patients typically appear normal at birth, with multisystem involvement developing over time.

System	Clinical Manifestations
Ocular	Ectopia lentis (lens dislocates downward and inward), severe myopia, glaucoma, retinal detachment. Dislocation usually occurs by 3–4 years of age.
Skeletal	Marfanoid habitus, tall stature, arachnodactyly, scoliosis, severe osteoporosis.
Vascular	Thromboembolism (represents the major cause of mortality).
CNS	Intellectual disability (variable IQ 30–75), psychiatric disorders (anxiety, depression, obsessive-compulsive behavior), seizures in ~20% of patients.
Cutaneous	Distinctive malar flush on cheeks, fair skin, and fair hair (hypopigmentation).

Investigations

Screening Tests

Cyanide-Nitroprusside Test: Urine turns deep red/magenta, detecting sulfhydryl groups. False negatives can occur with low protein intake, and false positives occur in cystinuria.
Newborn Screening (NBS): Detects elevated methionine. Note that it may miss B6-responsive forms or remethylation defects where methionine levels are low.

Confirmatory Tests

Plasma Amino Acids: Classic form shows elevated methionine, elevated homocysteine, and low cysteine. Remethylation defects show low methionine and elevated homocysteine.
Plasma Total Homocysteine (tHcy): Markedly elevated (>100 µmol/L; Normal <15 µmol/L).
Enzyme Assay: CBS activity measured in cultured fibroblasts or liver biopsy.
Genetic Analysis: Mutation analysis of the CBS gene located on chromosome 21q22.3.

Pyridoxine (B6) Challenge Test

Administer 100–500 mg of Vitamin B6 daily to determine B6 responsiveness (a key prognostic factor).
A significant drop in plasma homocysteine and methionine implies B6-Responsive Homocystinuria, which carries a milder phenotype.

Management

Specific Therapy

Therapy	Indication And Rationale
Vitamin B6 (Pyridoxine)	First-line for B6-responsive patients (~50%). High dose (200–500 mg/day) aiming to maintain plasma homocysteine <50 µmol/L. Requires co-supplementation with Folate and Vitamin B12 to optimize remethylation.
Dietary Restriction	For B6-non-responsive patients. Low methionine diet restricting animal protein (meat, dairy, eggs) and utilizing a methionine-free medical formula containing essential Cysteine.
Betaine (Trimethylglycine)	Adjunct for non-responsive cases. Donates a methyl group to remethylate homocysteine to methionine. Requires monitoring to prevent cerebral edema if Methionine exceeds 1000 µmol/L.

Supportive Care

Anticoagulation: Not routinely indicated prophylactically, but aggressive intravenous hydration is absolutely mandatory during surgery or illness to prevent thromboembolism.
Ocular and Skeletal: Regular ophthalmology follow-up for surgical management of dislocated lenses. Calcium and Vitamin D supplementation for bone health.

Prognosis

Untreated: Poor life expectancy due to severe vascular events, with a 50% mortality rate by age 20–30.
Treated: B6-responsive patients have an excellent prognosis with normal intelligence and lifespan if treated early. B6-non-responsive patients have good outcomes if diet and Betaine are started in the neonatal period, though late treatment cannot reverse established intellectual disability or lens dislocation.